Trials 29
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 40 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | O(6)-benzylguanine | “O(6)-benzylguanine (O(6)-BG), an inhibitor of host alkylation repair, and BCNU were studied in children with refractory/untreatable central nervous system tumors to determine...” PMID 17941066 ↗ Mar 200837“At registration, patients were randomized to Arm 1, which consisted of therapy with O(6)-benzylguanine (O(6)-BG) + BCNU 40 mg/m(2) (reduced dose) + radiation therapy (RT) (O6BG...” PMID 25407559 ↗ Nov 2014 “Temozolomide pharmacokinetics were evaluated in children receiving concurrent O(6)-benzylguanine (O(6)BG), which enhanced the hematological toxicity of temozolomide.” PMID 19430790 ↗ May 2009 “O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy” NCT00436436 ↗ “PURPOSE: Phase I trial to study the effectiveness of O(6)-benzylguanine given before surgery to patients who have malignant glioma.” NCT00002971 ↗ |
| Known as | NSC 637037 | “Mutant MGMT Gene Transfer Into Human Hematopoietic Progenitors to Protect Hematopoiesis During O6-Benzylguanine (BG, NSC 637037) and Carmustine Followed by Temozolomide Therapy...” NCT00003567 ↗1“A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Metatstatic Melanoma” NCT00005961 ↗ |
| Known as | O-Benzylguanine | “A Phase 2 Study of O-Benzylguanine (O-BG) and Temozolomide in Patients With Glioblastoma Progressing at Least 3 Months After Completion of Primary Treatment With Radiation...” NCT00436436 ↗ |
| Known as | O-BG | “A Phase 2 Study of O-Benzylguanine (O-BG) and Temozolomide in Patients With Glioblastoma Progressing at Least 3 Months After Completion of Primary Treatment With Radiation...” NCT00436436 ↗ |
| Known as | O6-Benzylguanine - O6-BG | “O6-Benzylguanine - O6-BG” NCT00613093 ↗ |
| Known as | O6-BG | “PURPOSE: This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor...” PMID 19188181 ↗ Feb 200910“PURPOSE: This pediatric phase I trial of O6-benzylguanine (O6BG) and temozolomide (TMZ) on a daily schedule for 5 days, every 28 days was performed to determine the...” PMID 16234526 ↗ Oct 2005 “This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and...” PMID 19289491 ↗ Mar 2009 “O(6)-benzylguanine (O(6)-BG), an inhibitor of host alkylation repair, and BCNU were studied in children with refractory/untreatable central nervous system tumors to determine...” PMID 17941066 ↗ Mar 2008 “Determine the dose of O6-benzylguanine (O6-BG) that produces total depletion of tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in more than 90% of patients with...” NCT00002971 ↗ “To determine the cutaneous T-cell Lymphoma (CTCL) response rate and safety of O6BG (O6-benzylguanine) /BCNU (carmustine) when given biweekly as two consecutive daily doses.” NCT00961220 ↗ “Temozolomide pharmacokinetics were evaluated in children receiving concurrent O(6)-benzylguanine (O(6)BG), which enhanced the hematological toxicity of temozolomide.” PMID 19430790 ↗ May 2009 “This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion” PMID 17264335 ↗ Feb 2007 “Patients receive O6-benzylguanine (O6-BG) IV over 1 hour followed 30 minutes later by oral temozolomide daily for 5 days.” NCT00020150 ↗ “Patients receive O(6)-benzylguanine (O6-BG) IV over 1 hour immediately followed by O6-BG IV continuously for 9 days.” NCT00045721 ↗ “Patients receive a single dose of O6-benzylguanine (O6-BG) IV over 1 hour at one of two dose levels.” NCT00003766 ↗ |
| Action | Inhibit | “baseline O6-alkylguanine DNA alkyltransferase (AGT) activity in circulating peripheral blood mononuclear cells decreases by greater than 90% at 2 hours after BG infusion.” NCT00002604 ↗ |
| Modality | Small molecule | “low molecular-weight purine analog” NCT05052957 ↗ |
| Route | Intravenous | “Patients receive BG IV over 1 hour during week 1” NCT00002604 ↗ |
| Target | AGT | “Correlate tumor tissue AGT depletion with AGT depletion in peripheral blood mononuclear cells (PBMC) obtained at a specified time after O6-BG administration” NCT00003766 ↗ |